148 related articles for article (PubMed ID: 3098444)
21. Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
Bonomi PD; Mladineo J; Morrin B; Wilbanks G; Slayton RE
Cancer Treat Rep; 1979 Jan; 63(1):137-8. PubMed ID: 105805
[No Abstract] [Full Text] [Related]
22. Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.
Garattini E; Colombo T; Donelli MG; Catalani P; Bianchi M; D'Incalci M; Pantarotto C
Cancer Chemother Pharmacol; 1983; 11(1):51-5. PubMed ID: 6411375
[TBL] [Abstract][Full Text] [Related]
23. Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
Edmonson JH; Wieand HS; McCormack GW
J Natl Cancer Inst; 1988 Sep; 80(14):1172-3. PubMed ID: 3137360
[No Abstract] [Full Text] [Related]
24. "Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?".
Bruckner HW
Cancer Treat Rep; 1987 Jun; 71(6):666-8. PubMed ID: 3107816
[No Abstract] [Full Text] [Related]
25. Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
Moore DH; Valea F; Crumpler LS; Fowler WC
Gynecol Oncol; 1993 Oct; 51(1):109-12. PubMed ID: 8244164
[TBL] [Abstract][Full Text] [Related]
26. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
27. The role of hexamethylmelamine in advanced ovarian carcinoma treatment.
Weiss RB
Gynecol Oncol; 1981 Oct; 12(2 Pt 1):141-9. PubMed ID: 6795094
[No Abstract] [Full Text] [Related]
28. Studies of the mode of action of antitumour triazenes and triazines-III. Metabolism studies on hexamethylmelamine.
Brindley C; Gescher A; Langdon SP; Broggini M; Colombo T; D'Incalci M
Biochem Pharmacol; 1982 Mar; 31(5):625-31. PubMed ID: 6805472
[TBL] [Abstract][Full Text] [Related]
29. Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers.
D'Incalci M; Farina P; Sessa C; Mangioni C; Garattini S
Cancer Treat Rep; 1982 Feb; 66(2):231-5. PubMed ID: 6799199
[TBL] [Abstract][Full Text] [Related]
30. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility.
Cumber AJ; Ross WC
Chem Biol Interact; 1977 Jun; 17(3):349-57. PubMed ID: 407012
[TBL] [Abstract][Full Text] [Related]
31. Hexamethylmelamine in mustard-resistant ovarian adenocarcinoma.
Omura GA; Greco FA; Birch R
Cancer Treat Rep; 1981; 65(5-6):530-1. PubMed ID: 6786741
[No Abstract] [Full Text] [Related]
32. Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine.
Paolini A; D'Incalci M
Cancer Treat Rep; 1986 Apr; 70(4):513-6. PubMed ID: 3084083
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect of trimelamol against human breast carcinoma xenografts in nude mice.
Yamada Y; Kubota T; Hoshiya Y; Asanuma F; Koh J; Kitajima M; Coley H; Judson I
Oncol Rep; 1996 Jul; 3(4):613-7. PubMed ID: 21594422
[TBL] [Abstract][Full Text] [Related]
34. Pre-clinical development of the anti-tumour agent CB 7646, bis N-(hydroxymethyl) trimethylmelamine, a stable analogue of trimelamol.
Coley HM; Jarman M; Brooks N; Kubota T; Goddard PM; Jones M; Lee N; Owens MD; Halbert GW; Judson IR
Int J Cancer; 1996 Nov; 68(3):356-63. PubMed ID: 8903478
[TBL] [Abstract][Full Text] [Related]
35. Combined effects of host antitumor immune responses and chemotherapy. Studies with hexamethylmelamine.
Tricarico M; Fuschiotti P; Ricci F; De Filippi R; Nunziata C; Pastore S; De Vecchis L
Chemioterapia; 1988 Jun; 7(3):203-7. PubMed ID: 3139307
[TBL] [Abstract][Full Text] [Related]
36. Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
Johnson BL; Fisher RI; Bender RA; DeVita VT; Chabner BA; Young RC
Cancer; 1978 Nov; 42(5):2157-61. PubMed ID: 102417
[TBL] [Abstract][Full Text] [Related]
37. [Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group].
Pinon G; Pinel MC; Goudier MJ; Coiffier B; Filippi MH; Goupil A; Roullet B; Facchini T; Mignot L; Tresca P
Bull Cancer; 1991; 78(12):1119-31. PubMed ID: 1786425
[TBL] [Abstract][Full Text] [Related]
38. Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.
Rosen GF; Lurain JR; Newton M
Gynecol Oncol; 1987 Jun; 27(2):173-9. PubMed ID: 3106174
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy of human tumors in T-lymphocyte-deficient mice.
Mitchley BC; Clarke SA; Connors TA; Carter SM; Neville AM
Cancer Treat Rep; 1977; 61(3):451-62. PubMed ID: 406045
[TBL] [Abstract][Full Text] [Related]
40. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Markman M; Blessing JA; Moore D; Ball H; Lentz SS
Gynecol Oncol; 1998 Jun; 69(3):226-9. PubMed ID: 9648592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
